Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Dull

Showing results (11-20 of 39) with videos related to

Pageof 4
Sort By:
Journal of the National Cancer Institute. Monographs|November 12, 2024
Human papillomavirus prophylactic vaccines: update on new vaccine development and implications for single-dose policyAnne E Schuind, Kanduri Ananth Balaji, Anna Du, et al.
Human Vaccines|September 10, 2011
The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humansDaniela Toneatto, Shevqet Ismaili, Ellen Ypma, et al.
The Journal of Pediatrics|March 25, 2014
Antibody persistence and booster response of a quadrivalent meningococcal conjugate vaccine in adolescentsRoger Baxter, Keith Reisinger, Stanley L Block, et al.
Trials|September 30, 2020
Moving fast but going slow: coordination challenges for trials of COVID-19 post-exposure prophylaxisDarrell H S Tan, Rupesh Agrawal, Ruanne V Barnabas, et al.
Lancet (London, England)|January 18, 2013
Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trialsTimo Vesikari, Susanna Esposito, Roman Prymula, et al.
The Pediatric Infectious Disease Journal|November 19, 2011
Safety and immunogenicity of a novel quadrivalent meningococcal CRM-conjugate vaccine given concomitantly with routine vaccinations in infantsNicola P Klein, Keith S Reisinger, William Johnston, et al.
Lancet (London, England)|March 26, 2021
WHO International Standard for anti-SARS-CoV-2 immunoglobulinPaul A Kristiansen, Mark Page, Valentina Bernasconi, et al.
The Pediatric Infectious Disease Journal|July 3, 2015
Persistence of Meningococcal Antibodies and Response to a Third Dose After a Two-dose Vaccination Series with Investigational MenABCWY Vaccine Formulations in AdolescentsXavier Saez-Llorens, Diana Catalina Aguilera Vaca, Katia Abarca, et al.
Msphere|September 27, 2019
Glycoconjugates: What It Would Take To Master These Well-Known yet Little-Understood Immunogens for Vaccine DevelopmentFikri Avci, Francesco Berti, Peter Dull, et al.
Vaccine|December 25, 2012
Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa?Eva Hong, Marzia Monica Giuliani, Ala-Eddine Deghmane, et al.
Pageof 4

Showing results (11-20 of 39) with videos related to

Sort By:
Pageof 4
Journal of the National Cancer Institute. Monographs|November 12, 2024
Human papillomavirus prophylactic vaccines: update on new vaccine development and implications for single-dose policyAnne E Schuind, Kanduri Ananth Balaji, Anna Du, et al.
Human Vaccines|September 10, 2011
The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humansDaniela Toneatto, Shevqet Ismaili, Ellen Ypma, et al.
The Journal of Pediatrics|March 25, 2014
Antibody persistence and booster response of a quadrivalent meningococcal conjugate vaccine in adolescentsRoger Baxter, Keith Reisinger, Stanley L Block, et al.
Trials|September 30, 2020
Moving fast but going slow: coordination challenges for trials of COVID-19 post-exposure prophylaxisDarrell H S Tan, Rupesh Agrawal, Ruanne V Barnabas, et al.
Lancet (London, England)|January 18, 2013
Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trialsTimo Vesikari, Susanna Esposito, Roman Prymula, et al.
The Pediatric Infectious Disease Journal|November 19, 2011
Safety and immunogenicity of a novel quadrivalent meningococcal CRM-conjugate vaccine given concomitantly with routine vaccinations in infantsNicola P Klein, Keith S Reisinger, William Johnston, et al.
Lancet (London, England)|March 26, 2021
WHO International Standard for anti-SARS-CoV-2 immunoglobulinPaul A Kristiansen, Mark Page, Valentina Bernasconi, et al.
The Pediatric Infectious Disease Journal|July 3, 2015
Persistence of Meningococcal Antibodies and Response to a Third Dose After a Two-dose Vaccination Series with Investigational MenABCWY Vaccine Formulations in AdolescentsXavier Saez-Llorens, Diana Catalina Aguilera Vaca, Katia Abarca, et al.
Msphere|September 27, 2019
Glycoconjugates: What It Would Take To Master These Well-Known yet Little-Understood Immunogens for Vaccine DevelopmentFikri Avci, Francesco Berti, Peter Dull, et al.
Vaccine|December 25, 2012
Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa?Eva Hong, Marzia Monica Giuliani, Ala-Eddine Deghmane, et al.
Pageof 4